Attovia Therapeutics, Inc. IPO
listed
| Exchange | Nasdaq |
| Ticker | ATTO |
| Price range | $15–17 |
| IPO price | $17 |
| Deal size | $289m |
| First-day close | $21.90 (+28.8%) |
| First trading day | 5 Aug 2026 |
| First filing seen | 29 Jul 2026 |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Carlos, CA |
| Incorporated in | DE |
Upsized to 17 million shares at $17 from 12.5 million at $15-$17. Phase 1 immune-disease biotech. Source does not say if size includes over-allotment.
SEC filings
| Form | What it is | Filed |
|---|---|---|
| S-1/A | Amended registration statement | 4 Aug 2026 |
| S-1/A | Amended registration statement | 29 Jul 2026 |
Deal terms: Renaissance Capital ↗ · Filings: SEC EDGAR ↗
This page reports public filings and reported deal terms. It is not a recommendation to buy, sell or apply.